Skip to content

MAZE MAZE Change in AP

Change in AP at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$35.6M+35.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$2.3M-294%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$5.68M-31.8%
Zymeworks logo
ZymeworksZYME
-$7.75M+63.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$461K+85.6%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$111K+89.4%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's change in AP?
MAZE (MAZE) reported change in AP of $2.21M in Q1 2026.
How has MAZE's change in AP changed year-over-year?
MAZE's change in AP increased by 282.0% year-over-year, from $579K to $2.21M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.